RMHI
Retrieve Medical Holdings Inc2.8200
+0.0200+0.71%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
72.40MP/E (TTM)
-Basic EPS (TTM)
-0.53Dividend Yield
0%Recent Filings
10-Q
Q1 FY2023 results
Peak Pharmaceuticals, a shell company, posted no revenue for Q1 FY2023 ended December 31, 2022, with operating expenses doubling y/y to $110k from $52k, driven by higher accounting fees including $46k to related parties. Operating loss widened to $110k from $52k y/y, while net loss hit $112k versus $59k last year, the $2k gap due to interest expense. Cash burned $31k in operations (derived), ending at $97k amid $706k liabilities exceeding $102k assets; multiple notes payable remain in default with no extensions. Stockholders' deficit grew to $603k. Controls ineffective. Debt defaults loom large.
8-K
Auditor switch to Marcum
Peak Pharmaceuticals dismissed Friedman LLP as its auditor on January 11, 2023, after Friedman's combination with Marcum LLP effective September 1, 2022, and promptly engaged Marcum for the fiscal year ending September 30, 2023. No disagreements or reportable events arose with Friedman, whose latest report flagged going concern doubts. Clean switch. Marcum had no prior consultations.
10-Q
Q3 FY2019 results
Peak Pharmaceuticals, a shell company, narrowed its Q3 operating loss to $1.5k from $3.0k y/y while interest expense rose to $2.2k from $1.3k, driving net loss to $3.7k versus $4.3k. Nine-month operating loss shrank to $4.2k from $18.2k y/y, with net loss at $10.2k; EPS holds at $(0.00) across 78.4M diluted shares, anti-dilution from convertibles excluded. Cash dwindled to $558, operating cash burn slowed to $1.7k (nine months), yet liabilities hit $232k including $20k convertibles and $43k notes at 12%. Cash is nearly gone. Defaulted debt looms large.
10-K
FY2018 results
Peak Pharmaceuticals posted zero revenue for FY2018 ended September 30, matching FY2017, while operating expenses fell to $27,823 from $44,987, mainly from lower accounting and filing fees. Net loss narrowed as interest expense rose to $5,584 yet change in fair value of convertible debt gained $5,000. Cash dwindled to $2,270 amid $43,721 operating outflows funded by $43,000 in promissory notes; working capital sits at $(221,092). A shell company hunting acquisitions. Auditors flag going concern doubts. No quarterly breakdowns disclosed.
10-Q
Q1 FY2019 results
Peak Pharmaceuticals, a shell company, trimmed its Q1 FY2019 operating loss to $953 from $7,025 y/y, thanks to lower G&A expenses including related-party fees, while net loss eased to $2,859 from $7,629—net driven by higher interest expense of $1,906 vs $604. Cash drained to $764, with operating cash use at $1,506 y/y (derived). Convertible notes total $20,000 (12%, due March 2019) plus $43,000 notes payable, all current amid $224K liabilities and $224K deficit. One repaid note post-period. Controls ineffective. Cash is vanishing fast.
BEAT
Heartbeam, Inc.
3.44+0.81
CCLD
CareCloud, Inc.
3.21+0.02
CMHSF
COMPREHENSIVE HEALTHCARE SYS IN
0.35+0.00
DH
Definitive Healthcare Corp.
2.29-0.01
HNGE
Hinge Health, Inc.
48.41-0.09
NUTX
Nutex Health Inc.
171.72-4.06
ONMD
OneMedNet Corp
1.41+0.17
RMD
ResMed Inc.
247.34-5.73
RMSL
RemSleep Holdings, Inc.
0.00+0.00
VSEE
VSee Health, Inc.
0.45-0.02